TACE plus immunotherapy and VEGF drug for unresectable liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether combining TACE (a liver-targeted chemo procedure) with two medicines—an immune “checkpoint” drug and a blood-vessel blocking drug—can control unresectable hepatocellular carcinoma. It’s designed for people who can’t have surgery or curative ablation, and who still have reasonably strong liver and overall health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–75 years old and have a confirmed diagnosis of liver cancer (not bile-duct cancer).
- Your cancer has at least one measurable spot on CT (size limits apply) and can’t be removed with surgery or cured with ablation.
- Your liver cancer stage is CNLC Ⅱa to Ⅲb, and your liver function is Child-Pugh A or B (about 5–7 points).
- Your overall strength/fitness is ECOG 0–1, and you’re expected to live at least 12 weeks.
- Your blood counts, kidneys, and other key organ tests are within required ranges.
- If you have hepatitis B (HBV), the virus level must be controlled and you must take antiviral treatment during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study combines a liver-directed procedure called TACE (which blocks blood flow to the tumor and delivers chemotherapy directly to it) with two immunotherapy drugs and a targeted therapy (bevacizumab). The goal is to see if this combination can shrink liver cancer that cannot be surgically removed, without the cancer having spread elsewhere.
This trial tests a new combination treatment for liver cancer that cannot be removed with surgery. It combines targeted therapy and immunotherapy with a procedure that delivers chemotherapy directly to the liver, aiming to shrink tumors and improve outcomes.
This trial tests a combination of two treatments for advanced liver cancer: TACE (a procedure that blocks the blood supply to the tumor) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). The goal is to see if this combination works better than either treatment alone and to understand how it affects the immune system around the tumor.
This trial tests a combination of treatments for liver cancer that cannot be removed with surgery. It uses a procedure to block the tumor's blood supply plus two drugs that help the immune system fight the cancer. This may help shrink tumors and slow the disease.
This trial tests whether adding a liver-directed treatment to standard systemic therapy can improve outcomes for people with liver cancer that cannot be removed. It may help shrink tumors or slow the disease while on current treatment.
This trial studies whether a combination of immune therapy (atezolizumab) and a blood-vessel-targeting drug (bevacizumab) works better than a standard procedure called TACE for people with intermediate-stage liver cancer (HCC). It may help shrink tumors and help patients live longer with fewer complications.
Hear when a new Adebrelimab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.